BostonGene is heading to Houston for SOHO2026 to present two abstracts showcasing novel genomic classifier and immunotherapy selection frameworks designed to extract actionable insights from complex multimodal datasets.

BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and AI. Built and validated across an extensive real-world clinical network, BostonGene’s foundation model of cancer and the immune system integrates genomic, transcriptomic, immune, and clinical outcome data to map the complexities of the tumor microenvironment and generate biologically grounded, actionable insights. These insights enable biopharma partners to accelerate discovery timelines, de-risk clinical trials, identify novel targets, and optimize therapeutic responses across all stages of development, while also advancing clinically integrated patient care. BostonGene has established unrivaled credibility across oncology and immunology through a collaborative ecosystem of deep academic partnerships with MD Anderson Cancer Center, Memorial Sloan Kettering, Dana Farber Cancer Institute, the Mayo Clinic, and other leading cancer institutions across the globe. These are complemented by strategic business partnerships with AstraZeneca, Johnson & Johnson, Takeda, Ottimo Pharma, and other global pharma and biotech leaders leveraging BostonGene’s platform to drive precision medicine. Its work is reflected in more than 200 publications in top peer-reviewed journals, including Nature, Cancer Cell, and Cancer Discovery. The company's industry-leading innovation has been recognized with awards such as Frost & Sullivan’s 2025 Global Technology Innovation Leadership Award in AI-driven Precision Oncology Solutions, as well as BioTech Breakthrough’s 2025 Overall Immunology Company of the Year and 2025 AI-based Drug Discovery Solution of the Year.